“Rare diseases are quite common”
Rare diseases are individually rare but collectively affect millions of people worldwide. Yet, they remain under-researched and are often misdiagnosed.
Search
cat feline diabetes medication treatment fda approval
Boehringer Ingelheim receives FDA approval for SENVELGO®
New positive data in Phase III type 2 diabetes trial
DINAMO Phase III trial demonstrated empagliflozin significantly reduced blood sugar levels in children and adolescents with type 2 diabetes
Phase II clinical trial weight loss results
Data shows nearly 19% weight loss in people with overweight or obesity in Phase II trial with survodutide (BI 456906)
Boehringer founding sponsor of CKM Health Initiative
Boehringer Ingelheim founding sponsor of AHA's Cardiovascular-Kidney-Metabolic Health Initiative
Geographic Atrophy
Geographic atrophy (GA) is an advanced and severe form of dry age-related macular degeneration (AMD) that progresses slowly but can lead to permanent vision loss.
Respimat media
Diabetic macular edema and diabetic macular ischemia
Diabetic macular edema and diabetic macular ischemia are complications of diabetic retinopathy.
EMPRISE-Study
EMPRISE-Study
additional-investment-in-Lyon-Jonage
Boehringer Ingelheim to expand veterinary vaccine capacity for emerging and transboundary diseases in France
Award: Boehringer Ingelheim is Global Top Employer 2022
Global Top Employer 2022
Boehringer Ingelheim appointment to Board Managing Directors
Boehringer Ingelheim announces appointments to Board of Managing Directors
Animal Welfare through environmental sustainability
Producing honey and contributing to environmental sustainability during your work hours.
CD137/FAP agonist
CD137/FAP agonist
NEJM-IL-36-Phase-1-GPP-data
Data published in The New England Journal of Medicine show rapid improvement of symptoms in patients with a rare form of pustular psoriasis
Boehringer Ingelheim Venture Fund invests precision antimicrobials
Boehringer Ingelheim Venture Fund invests in the development of precision antimicrobials
Big molecules - Huge potential | Bioxcellence | Boehringer Ingelheim
Explore the potential of big molecules with BioXcellence, offering advanced biopharmaceutical production services to unlock new possibilities in healthcare.
Cooperation with Google Quantum AI
FDA- HFpEF-breakthrough-designation-EMPEROR-preserved
U.S. FDA issues Breakthrough Therapy Designation for the treatment of adults with heart failure with preserved ejection fraction
emperor-preserved-heart-failure-toplineresults
Positive, top-line results announced from the EMPEROR-Preserved Phase III trial in adults with heart failure with preserved ejection fraction
FDA accepts new chronic kidney disease treatment application
FDA accepts new chronic kidney disease treatment application
environmental sustainability commitments
On the occasion of the 2021 UN Climate Change Conference (COP26), Boehringer Ingelheim shares an update on its strategic approach to sustainability
FDA-CRL-T1D
US FDA issues complete response letter for treatment of adults with type 1 diabetes
Diabetic Retinopathy
Diabetic retinopathy affects 1 in 3 people with diabetes and is the leading cause of vision loss in adults of working age.
emperor-preserved-chmp-positive-opinion
CHMP issues positive opinion to expand Jardiance (empagliflozin) indication based on unprecedented benefit in adult heart failure patients with preserved ejection fraction